The starting point: Succession in a phase of strategic decision-making.
An international pharmaceutical company with a German commercial unit was facing a sensitive transition. The Medical Director for Germany had relocated, and the geographical distance to the German company's headquarters made continuing in the role impractical in the medium term.
The market environment for menopausal hormone therapy was simultaneously undergoing a remarkable reassessment. The lingering uncertainty stemming from the Women's Health Initiative had long influenced prescribing practices in Germany; the coverage rate is around 18 percent for symptomatic women, and the AWMF's S3 guideline on peri- and postmenopause is far from being operationalized in all practices. At the same time, international evidence is correcting this picture: The German Menopause Society speaks openly of a renaissance of differentiated, individualized HRT, and the FDA removed the black box warning for estrogen preparations at the end of 2025.
At the market level, the logic of the business is simultaneously shifting. Established hormone therapy drugs are widely genericized; generic estradiol and progesterone preparations dominate the market, with generics accounting for over 78 percent of hormone therapies. Pharmacies are obligated under Section 129 of the German Social Code, Book V (SGB V), to preferentially dispense the discounted drug of the respective health insurance fund. The "aut idem" (same active ingredient) designation is only permitted in medically justified individual cases. The originator thus loses direct control over prescribing decisions at the point of sale.
It was precisely within this constellation that the German subsidiary planned the launch of an indication extension and, in parallel, the medium-term entry into a second business area: an accompanying digital health application for menopausal symptom recording and therapy support, designed for a later fast-track submission according to § 139e SGB V to the BfArM.
Market segment:
Rx-Pharma specialty therapeutics
MANDATE:
Medical Advisor Dermatology with responsibility for KOL management, scientific positioning and launch preparation
ENVIRONMENT:
Medium-sized pharmaceutical company with an established dermatology portfolio
STATUS:
Exclusive direct search mandate / open succession search
REGION: Germany
IMPACT:
Securing scientific competitiveness in a transforming therapeutic field.
Building a robust KOL network with leading dermatological clinics and private practitioners in the DACH region.
What was at stake?
A delayed or incorrect appointment would have affected the company in three dimensions simultaneously. Firstly, in its core business: The upcoming product launch depends on the quality of the scientific preparation, the involvement of professional societies, the advisory board architecture, and the activation of the MSL team by a medical community that, after two decades of WHI shadows, is only now beginning to rebuild trust in modern hormone therapy.
Without medical leadership, a launch without scientific backing is likely, with direct consequences for prescription dynamics and market share.
Secondly, within the KOL network: Leading opinion leaders in women's health are personally, not institutionally, connected. The departure of a respected Medical Director without an adequate successor would have severed lines of communication that had been built up over years and weakened access to conferences, guideline development, and publications.
Thirdly, regarding the digital strategy: The planned entry into DiGA (Digital Health Applications) requires a foundation of clinical evidence, study design, health services research, and medical validation, which first needs to be established. A DiGA for menopausal symptoms stands or falls with the demonstration of a positive healthcare effect according to the DiGAV (German Digital Health Applications Ordinance), and a Medical Director must scientifically justify precisely this foundation long before an application is even submitted to the BfArM (Federal Institute for Drugs and Medical Devices). An incorrect appointment would not only have damaged the prescription drug launch but also the medium-term digital agenda, with a corresponding investment risk.
Our approach: Professionally appropriate, regionally rooted, culturally compatible
The company had just undergone a generational change at its top. They were not looking for an executive to maintain the status quo, but rather a medical professional ready to lead the company into its next phase, with the courage to break new ground and actively shape the transition between traditional prescription drug business and digital healthcare.
Andris Consulting has therefore designed the mandate as a senior management mandate with three equally important requirement dimensions: professional suitability for the upcoming task, personal anchoring in the region and cultural compatibility with a family business undergoing generational change.
The technical dimension addressed a situation that has long been a reality in this market segment. Established active ingredients are widely subject to generic competition, and pharmacists are obligated to dispense the discounted drug. For the medical affairs function, this represents a paradigm shift in daily practice. Differentiation can no longer be achieved solely through original clinical evidence, but requires a healthcare-oriented evidence logic: real-world evidence, registry data, patient-reported outcomes, adherence studies, quality of life, and differentiation based on formulation and ease of use. At the same time, stakeholder engagement is shifting. Key opinion leader (KOL) engagement in the traditional sense remains important, but is no longer sufficient when physicians' prescribing decisions are effectively controlled by substitution rules and fixed reimbursement amounts. Medical affairs is becoming the interface between science, health insurance companies, healthcare research, and patient organizations. In addition, there is the preparation for the Rx launch in a new indication and the scientific development of the evidence architecture for the later DiGA perspective according to § 139e SGB V. Andris Consulting has therefore deliberately focused its search on candidates from the corporate environment, where structured medical affairs processes, professional lifecycle management, real-world evidence building and launch excellence are part of everyday life.
The regional dimension was crucial for the long-term success of this mandate. Our experience as pharmaceutical headhunters shows that an executive's personal circumstances often have a greater impact on the long-term success of a placement than the most specific technical qualifications. The previous appointee ultimately relinquished the mandate due to a personal relocation within Germany. This experience, gained directly from the client's own organization, was incorporated into the job requirements. Therefore, we exclusively targeted candidates who have strong personal ties to the rural region surrounding the German commercial headquarters, with established family and social connections that make a long-term commitment realistic.
In a family-owned company undergoing generational change, the cultural dimension was the most sensitive. The new management team sought a Medical Director who would respect the diligence and values of a family business while simultaneously leveraging the flexibility afforded by short decision-making distances. Therefore, in the selection process, Andris Consulting not only assessed professional qualifications and leadership skills but also systematically considered the candidates' overall situation: biography, personal circumstances, previous cultural influences within a corporate environment, and willingness to contribute to the development of a family-run, medium-sized company. As a specialized personnel consultancy for the pharmaceutical industry, we firmly believe that successful senior management appointments are only possible when professional background, personal circumstances, leadership personality, and corporate culture align perfectly. One of these factors alone is insufficient; all four together ensure a sustainable appointment.
The result
Credibility at launch, foundation for the future
Andris Consulting has gained a medical leader with a corporate background who brings professional medical affairs processes and experience in evidence-based positioning in a therapeutic area burdened by legacy studies and facing increasing generic drug pressure. Personally, he has deep roots in the region where the German commercial headquarters is located and is culturally compatible with a family business undergoing generational change.
The Rx launch for the new indication was prepared seamlessly. Advisory boards were restructured with key opinion leaders (KOLs), communication with healthcare professionals was adjusted to reflect the updated evidence base, the medical supply chain (MSL) team was trained on the new data, and integration into the guideline development of the German Society for Gynecology and Obstetrics (DGGG) and the German Society for Gynecology and Obstetrics (DMG) was stabilized. Simultaneously, the originator's scientific differentiation strategy was refined in the generics-dominated market, with real-world evidence initiatives and a clear, patient-centered line of argumentation directed toward professional societies and payers. The orderly transition prevented the severance of KOL relationships.
Under the new medical leadership, the scientific foundation for the planned digital health application (DiGA) was laid. Study design, endpoint architecture, and considerations for demonstrating the positive healthcare effect according to Section 139e of the German Social Code, Book V (SGB V) were established, and collaborations with healthcare researchers and potential study centers were initiated. The fast-track submission to the Federal Institute for Drugs and Medical Devices (BfArM) remains a medium-term project, which is being prepared under the new medical leadership.
The mandate awarded to Andris Consulting has not only resolved the acute succession issue, but has also enabled the German company to pursue the Rx launch, the defense of its originator position in the market under generic pressure, and the development of its digital business under coherent medical leadership.
Market segment
OTC Pharma & Consumer Healthcare
MANDATE
Marketing Director (Pharmacy-Consumer Health Brands)
ENVIRONMENT
Medium-sized OTC pharmaceutical company with >500 employees
STATUS
Exclusive Direct Search Mandate
REGION
Germany
Impact
Rejuvenation of the customer target group
Double-digit growth
Frequently Asked Questions in the Specialty Pharmaceuticals Sector
We're not starting from scratch. We leverage an established network, continuously map the market, and anticipate market changes. Through our exclusive direct search, we reach precisely the individuals who are a good professional fit and open to new opportunities.
Access to medical professionals is becoming noticeably more restricted. At the same time, the level of technical complexity is increasing dramatically. Simply presenting a good product is no longer sufficient. Pharmaceutical companies must now position themselves as true strategic partners. They must offer clear added value beyond the product itself.
Managers must be able to develop an omnichannel strategy that solves the healthcare provider access problem. Long-term employees must be included in the transformation to a modern structure. This requires sensitivity to avoid overwhelming the workforce (and the works council). Specialized key account managers must understand their target group down to the smallest detail and be able to communicate and persuade the chief physician and the administrative director on equal footing. They must be familiar with the actual needs on the ground. Successful approaches today include concrete projects that make the daily work of medical professionals easier.
We act as your extended arm in the market. All communication is completely confidential. Your company name will only be revealed once our fundamental interest and professional qualifications have been unequivocally established.
We use state-of-the-art technology. This makes us efficient. But the algorithm doesn't understand human nuances. We focus on in-depth expertise and personal connection instead of mindless keyword searches. We clarify cultural fit through personal dialogue. We combine the process reliability of a large consulting firm with the exclusivity of a specialized partner. Mass recruitment is completely out of the question for us.
In today's job market, these factors are crucial. Those who fail to demonstrate flexibility lose their appeal. Top talent today actively seeks roles with societal impact. We address these values right from the initial contact. This ensures that the candidate's vision aligns with your company culture. Our expertise in this area is regularly discussed in specialist publications such as Healthrelations .
- Error: empty slot
- Error: empty slot
- Error: empty slot
- Error: empty slot
- Error: empty slot